Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation and Function by Mitogen-activated Protein Kinase

Increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been observed in several systems to correlate with a decreased ability of the insulin receptor to tyrosine-phosphorylate this endogenous substrate and to inhibit its subsequent association with phosphatidylinositol 3-kinase. In the present studies we have examined the potential role of the mitogen-activated protein (MAP) kinase in the increased serine phosphorylation of IRS-1 observed in human embryonic kidney cells treated with an activator of protein kinase C, phorbol 12-myristate 13-acetate. First, recombinantly produced kinase was shown to phosphorylate intact IRS-1 in a way that decreased the ability of isolated insulin receptor to phosphorylate the tyrosines recognized by the SH2 domains of the phosphatidylinositol 3-kinase. Second, an inhibitor of MAP kinase activation, PD98059, blocked the phorbol 12-myristate 13-acetate-induced inhibition of the insulin-stimulated increase in IRS-1 associated phosphatidylinositol 3-kinase. Third, activation of MAP kinase in intact cells via a regulatable upstream kinase, a RAF:estrogen receptor construct, could also inhibit the insulin-stimulated increase in IRS-1-associated phosphatidylinositol 3-kinase. Fourth, an in gel kinase assay showed that MAP kinase was the primary renaturable kinase in cell extracts capable of an IRS-1 IRS-1 was to in studies with endogenous MAP studies MAP kinase of the capable of and IRS-1 Increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been observed in several systems to correlate with a decreased ability of the insulin receptor to tyrosine-phosphorylate this endogenous substrate and to inhibit its subsequent association with phosphatidylinositol 3-kinase. In the present studies we have examined the potential role of the mitogen-activated protein (MAP) kinase in the increased serine phosphorylation of IRS-1 observed in human embryonic kidney cells treated with an activator of protein kinase C, phorbol 12-myristate 13-acetate. First, recombinantly produced kinase was shown to phosphorylate intact IRS-1 in a way that decreased the ability of isolated insulin receptor to phosphorylate the tyrosines recognized by the SH2 domains of the phosphatidylinositol 3-kinase. Second, an inhibitor of MAP kinase activation, PD98059, blocked the phorbol 12-myristate 13-acetate-induced inhibition of the insulin-stimulated increase in IRS-1 associated phosphatidylinositol 3-kinase. Third, activation of MAP kinase in intact cells via a regulatable upstream kinase, a RAF:estrogen receptor construct, could also inhibit the insulin-stimulated increase in IRS-1-associated phosphatidylinositol 3-kinase. Fourth, an in gel kinase assay showed that MAP kinase was the primary renaturable kinase in cell extracts capable of an IRS-1 IRS-1 was to in studies with endogenous MAP studies MAP kinase of the capable of and IRS-1 receptor substrate-1 insulin receptor protein kinase phorbol 12-myristate insulin mitogen-activated human embryonic gel MAP kinase insulin receptor protein kinase phorbol 12-myristate insulin mitogen-activated human embryonic gel MAP kinase a endogenous substrate of the insulin receptor kinase, phosphorylation insulin a protein a of and of the of of IRS-1 to to a of an increase in the and in the cell and the of the kinase to the of insulin of and IRS-1 potential phosphorylation to a of with the SH2 of and several in insulin activation of protein kinase of the inhibitor activation of by and a in insulin-stimulated phosphorylation of IRS-1 the by has been to of the and has been that increased serine phosphorylation of IRS-1 in subsequent inhibition of its phosphorylation by the insulin receptor In IRS-1 serine phosphorylation and insulin in by kinase In IRS-1 in the a recognized by of the MAP kinase of of potential phosphorylation and to the serine activation in a human kidney cell and a IRS-1 this by and MAP kinase to by the activation of and the MAP kinase kinase potential the phosphorylation of IRS-1 this of MAP the protein and MAP kinase, by a of a and and of the to the of the MAP kinase have been in insulin studies have shown that activation, in cells with and in cells IRS-1 in decreased insulin-stimulated phosphorylation of IRS-1 and a in its subsequent association with in In the in in kinase was observed this inhibition was to to the activation of a serine kinase capable of IRS-1 and a the to serine of a serine in this also to inhibit the ability of the to phosphorylate the in this to in IRS-1 the present studies the kinase IRS-1 and this IRS-1 phorbol 12-myristate the serine phosphorylation in this to a MAP kinase phosphorylation we the that MAP kinase was this of to this the of a inhibitor of the upstream of MAP kinase, in phosphorylation of IRS-1 and its by of a regulatable that MAP kinase could in was was a was to was was to MAP kinase was to the receptor was was a of was was was and was and IRS-1 by the and the the of of was the of IRS-1 a of the was to protein to and of the a of of in cells was with cells in with and a of was cells and a and with was with of and of protein was kinase of cells with in and to with was with of and of protein was and IRS-1 was with in was in cells by cell in in cells the to cells in and an and in and cell of by with to the cell and in of IRS-1 and of cells and treated with by in the of the by with in the of with and and treated with by with in and in and with to protein to IRS-1 the in and and in and the by in gel of the by and to the was with an to and by of by in in and with the a to a to by by to and with of the was by and the of associated IRS-1 was to the of IRS-1 present in and was the of phosphorylation in the cells cells and treated with of by with and with and and the with to protein with of and of the was and the was by the and of IRS-1 by cells and in with to protein in and in of with of in kinase and of was in of MAP kinase and of in and in in gel and by to with to and by and with was with that was to MAP kinase in of the was of cells treated with by of the with of to and with of of of the to IRS-1 in the of and and in by in and IRS-1 was and by to of with of the was in a a of the in and was with to and by with with and with was by and to the IRS-1 present in of IRS-1 by and with and by with of by and and and of to IRS-1 and and of by the of of and the by and cells treated with and in with to the in and the was with of IRS-1 and of kinase and of of to the and the of IRS-1 and cells and cells with and treated with and and and the with to protein IRS-1 with of kinase with IRS-1 by by to and with to and with to IRS-1 that been with kinase and to of and by and IRS-1 and by and to was by with to and IRS-1 and of cells treated with in of an by a of and and in to in of and in by with in and of MAP of cells treated with cells treated with to of a by to and with MAP kinase studies have that increased phosphorylation of IRS-1 by a of with the ability of this to insulin and its ability to with the studies have several in the IRS-1 with this of serine in the MAP kinase phosphorylation In the present studies we that MAP kinase phosphorylate IRS-1 and in the subsequent inhibition of insulin First, we have that and cells have the ability to phosphorylate IRS-1 and a to the serine of IRS-1 Second, we that the renaturable in cell cells phosphorylate an IRS-1 protein with and Third, the phosphorylation of IRS-1 by the ability of the to phosphorylate IRS-1 that the of the SH2 domains the phosphorylation of IRS-1 in in an inhibition of insulin that observed in intact cells that have been treated with Fourth, inhibition of insulin in an to and a inhibitor of PD98059, blocked the ability of to inhibit insulin also the ability of to the activation of the IRS-1 kinase, an inhibitor of the kinase was to inhibit the activation of this kinase the of IRS-1 cells in the of an the that MAP kinase the phosphorylation of IRS-1 in in its subsequent decreased ability to its with 3-kinase. present studies the that phosphorylate IRS-1 and also to an inhibition of insulin that studies have also a potential role MAP kinase in a inhibition of insulin studies have that the MAP in the phosphorylation of in the of the and the of activation In a in insulin was in cells a the MAP kinase has also been that with insulin activation of by a that with the that could to insulin by MAP kinase activation has been observed in of the that an of MAP kinase with of an increase in the of the IRS-1 serine kinase MAP in the of receptor substrate-1 insulin receptor protein kinase phorbol 12-myristate insulin mitogen-activated human embryonic gel MAP kinase insulin receptor protein kinase phorbol 12-myristate insulin mitogen-activated human embryonic gel MAP kinase a endogenous substrate of the insulin receptor kinase, phosphorylation insulin a protein a of and of the of of IRS-1 to to a of an increase in the and in the cell and the of the kinase to the of insulin of and IRS-1 potential phosphorylation to a of with the SH2 of and several in insulin activation of protein kinase of the inhibitor activation of by and a in insulin-stimulated phosphorylation of IRS-1 the by has been to of the and has been that increased serine phosphorylation of IRS-1 in subsequent inhibition of its phosphorylation by the insulin receptor In IRS-1 serine phosphorylation and insulin in by kinase In IRS-1 in the a recognized by of the MAP kinase of of potential phosphorylation and to the serine activation in a human kidney cell and a IRS-1 this by and MAP kinase to by the activation of and the MAP kinase kinase potential the phosphorylation of IRS-1 this of MAP the protein and MAP kinase, by a of a and and of the to the of the MAP kinase have been in insulin studies have shown that activation, in cells with and in cells IRS-1 in decreased insulin-stimulated phosphorylation of IRS-1 and a in its subsequent association with in In the in in kinase was observed this inhibition was to to the activation of a serine kinase capable of IRS-1 and a the to serine of a serine in this also to inhibit the ability of the to phosphorylate the in this to in IRS-1 the present studies the kinase IRS-1 and this IRS-1 phorbol 12-myristate the serine phosphorylation in this to a MAP kinase phosphorylation we the that MAP kinase was this of to this the of a inhibitor of the upstream of MAP kinase, in phosphorylation of IRS-1 and its by of a regulatable that MAP kinase could in was was a was to was was to MAP kinase was to the receptor was was a of was was was and was and IRS-1 by the and the the of of was the of IRS-1 a of the was to protein to and of the a of of in cells was with cells in with and a of was cells and a and with was with of and of protein was kinase of cells with in and to with was with of and of protein was and IRS-1 was with in was in cells by cell in in cells the to cells in and an and in and cell of by with to the cell and in of IRS-1 and of cells and treated with by in the of the by with in the of with and and treated with by with in and in and with to protein to IRS-1 the in and and in and the by in gel of the by and to the was with an to and by of by in in and with the a to a to by by to and with of the was by and the of associated IRS-1 was to the of IRS-1 present in and was the of phosphorylation in the cells cells and treated with of by with and with and and the with to protein with of and of the was and the was by the and of IRS-1 by cells and in with to protein in and in of with of in kinase and of was in of MAP kinase and of in and in in gel and by to with to and by and with was with that was to MAP kinase in of the was of cells treated with by of the with of to and with of of of the to IRS-1 in the of and and in by in and IRS-1 was and by to of with of the was in a a of the in and was with to and by with with and with was by and to the IRS-1 present in of IRS-1 by and with and by with of by and and and of to IRS-1 and and of by the of of and the by and cells treated with and in with to the in and the was with of IRS-1 and of kinase and of of to the and the of IRS-1 and cells and cells with and treated with and and and the with to protein IRS-1 with of kinase with IRS-1 by by to and with to and with to IRS-1 that been with kinase and to of and by and IRS-1 and by and to was by with to and IRS-1 and of cells treated with in of an by a of and and in to in of and in by with in and of MAP of cells treated with cells treated with to of a by to and with MAP kinase was was a was to was was to MAP kinase was to the receptor was was a of was was was and was and IRS-1 by the was was a was to was was to MAP kinase was to the receptor was was a of was was was and was and IRS-1 by the and the the of of was the of IRS-1 a of the was to protein to and of the a of of in cells was with cells in with and a of was cells and a and with was with of and of protein was kinase of cells with in and to with was with of and of protein was and IRS-1 was with in was in cells by cell in in cells the to cells in and an and in and cell of by with to the cell and in of IRS-1 and of cells and treated with by in the of the by with in the of with and and treated with by with in and in and with to protein to IRS-1 the in and and in and the by in gel of the by and to the was with an to and by of by in in and with the a to a to by by to and with of the was by and the of associated IRS-1 was to the of IRS-1 present in and was the of phosphorylation in the cells cells and treated with of by with and with and and the with to protein with of and of the was and the was by the and of IRS-1 by cells and in with to protein in and in of with of in kinase and of was in of MAP kinase and of in and in in gel and by to with to and by and with was with that was to MAP kinase in of the was of cells treated with by of the with of to and with of of of the to IRS-1 in the of and and in by in and IRS-1 was and by to of with of the was in a a of the in and was with to and by with with and with was by and to the IRS-1 present in of IRS-1 by and with and by with of by and and and of to IRS-1 and and of by the of of and the by and cells treated with and in with to the in and the was with of IRS-1 and of kinase and of of to the and the of IRS-1 and cells and cells with and treated with and and and the with to protein IRS-1 with of kinase with IRS-1 by by to and with to and with to IRS-1 that been with kinase and to of and by and IRS-1 and by and to was by with to and IRS-1 and of cells treated with in of an by a of and and in to in of and in by with in and of MAP of cells treated with cells treated with to of a by to and with MAP kinase and the the of of was the of IRS-1 a of the was to protein to and of the a of of in cells was with cells in with and a of was cells and a and with was with of and of protein was kinase of cells with in and to with was with of and of protein was and IRS-1 was with in was in cells by cell in in cells the to cells in and an and in and cell of by with to the cell and in of IRS-1 and of cells and treated with by in the of the by with in the of with and and treated with by with in and in and with to protein to IRS-1 the in and and in and the by in gel of the by and to the was with an to and by of by in in and with the a to a to by by to and with of the was by and the of associated IRS-1 was to the of IRS-1 present in and was the of phosphorylation in the cells cells and treated with of by with and with and and the with to protein with of and of the was and the was by the and of IRS-1 by cells and in with to protein in and in of with of in kinase and of was in of MAP kinase and of in and in in gel and by to with to and by and with was with that was to MAP kinase in of the was of cells treated with by of the with of to and with of of of the to IRS-1 in the of and and in by in and IRS-1 was and by to of with of the was in a a of the in and was with to and by with with and with was by and to the IRS-1 present in of IRS-1 by and with and by with of by and and and of to IRS-1 and and of by the of of and the by and cells treated with and in with to the in and the was with of IRS-1 and of kinase and of of to the and the of IRS-1 and cells and cells with and treated with and and and the with to protein IRS-1 with of kinase with IRS-1 by by to and with to and with to IRS-1 that been with kinase and to of and by and IRS-1 and by and to was by with to and IRS-1 and of cells treated with in of an by a of and and in to in of and in by with in and of MAP of cells treated with cells treated with to of a by to and with MAP kinase and the the of of was the of IRS-1 a of the was to protein to and of the a of of in cells was with cells in with and a of was cells and a and with was with of and of protein was kinase of cells with in and to with was with of and of protein was the the of of was the of IRS-1 a of the was to protein to and of the a of of in cells was with cells in with and a of was cells and a and with was with of and of protein was kinase of cells with in and to with was with of and of protein was and IRS-1 was with in was in cells by cell in in cells the to cells in and an and in and cell of by with to the cell and in IRS-1 was with in was in cells by cell in in cells the to cells in and an and in and cell of by with to the cell and in In of IRS-1 and of cells and treated with by in the of the by with in the of with and and treated with by with in and in and with to protein to IRS-1 the in and and in and the by in gel of the by and to the was with an to and by of by in in and with the a to a to by by to and with of the was by and the of associated IRS-1 was to the of IRS-1 present in and was the of phosphorylation in the cells of cells and treated with by in the of the by with in the of with and and treated with by with in and in and with to protein to IRS-1 the in and and in and the by in gel of the by and to the was with an to and by of by in in and with the a to a to by by to and with of the was by and the of associated IRS-1 was to the of IRS-1 present in and was the of phosphorylation in the cells cells and treated with of by with and with and and the with to protein with of and of the was and the was by the and cells and treated with of by with and with and and the with to protein with of and of the was and the was by the and In of IRS-1 by cells and in with to protein in and in of with of in kinase and of was in of MAP kinase and of in and in in gel and by to with to and cells and in with to protein in and in of with of in kinase and of was in of MAP kinase and of in and in in gel and by to with to and by and with was with that was to MAP kinase in of the was of cells treated with by of the with of to and with of of of the to IRS-1 in the of and and in by in and IRS-1 was and by to of with of the was in a a of the in and was with to and by with with and with was by and to the IRS-1 present in IRS-1 was with that was to MAP kinase in of the was of cells treated with by of the with of to and with of of of the to IRS-1 in the of and and in by in and IRS-1 was and by to of with of the was in a a of the in and was with to and by with with and with was by and to the IRS-1 present in of IRS-1 by and with and by with of by and and and of to IRS-1 and and of by the of of and the by and cells treated with and in with to the in and the was with of IRS-1 and of kinase and of of to the and the with and by with of by and and and of to IRS-1 and and of by the of of and the by and cells treated with and in with to the in and the was with of IRS-1 and of kinase and of of to the and the of IRS-1 and cells and cells with and treated with and and and the with to protein IRS-1 with of kinase with IRS-1 by by to and with to and with to IRS-1 that been with kinase and to of and by and IRS-1 and by and to was by with to and IRS-1 and cells and cells with and treated with and and and the with to protein IRS-1 with of kinase with IRS-1 by by to and with to and with to IRS-1 that been with kinase and to of and by and IRS-1 and by and to was by with to and IRS-1 and In of cells treated with in of an by a of and and in to in of and in by with in and of cells treated with in of an by a of and and in to in of and in by with in and of MAP of cells treated with cells treated with to of a by to and with MAP kinase of cells treated with cells treated with to of a by to and with MAP kinase studies have that increased phosphorylation of IRS-1 by a of with the ability of this to insulin and its ability to with the studies have several in the IRS-1 with this of serine in the MAP kinase phosphorylation In the present studies we that MAP kinase phosphorylate IRS-1 and in the subsequent inhibition of insulin First, we have that and cells have the ability to phosphorylate IRS-1 and a to the serine of IRS-1 Second, we that the renaturable in cell cells phosphorylate an IRS-1 protein with and Third, the phosphorylation of IRS-1 by the ability of the to phosphorylate IRS-1 that the of the SH2 domains the phosphorylation of IRS-1 in in an inhibition of insulin that observed in intact cells that have been treated with Fourth, inhibition of insulin in an to and a inhibitor of PD98059, blocked the ability of to inhibit insulin also the ability of to the activation of the IRS-1 kinase, an inhibitor of the kinase was to inhibit the activation of this kinase the of IRS-1 cells in the of an the that MAP kinase the phosphorylation of IRS-1 in in its subsequent decreased ability to its with 3-kinase. present studies the that phosphorylate IRS-1 and also to an inhibition of insulin that studies have also a potential role MAP kinase in a inhibition of insulin studies have that the MAP in the phosphorylation of in the of the and the of activation In a in insulin was in cells a the MAP kinase has also been that with insulin activation of by a that with the that could to insulin by MAP kinase activation has been observed in of the that an of MAP kinase with of an increase in the of the IRS-1 serine kinase MAP in the of studies have that increased phosphorylation of IRS-1 by a of with the ability of this to insulin and its ability to with the studies have several in the IRS-1 with this of serine in the MAP kinase phosphorylation In the present studies we that MAP kinase phosphorylate IRS-1 and in the subsequent inhibition of insulin First, we have that and cells have the ability to phosphorylate IRS-1 and a to the serine of IRS-1 Second, we that the renaturable in cell cells phosphorylate an IRS-1 protein with and Third, the phosphorylation of IRS-1 by the ability of the to phosphorylate IRS-1 that the of the SH2 domains the phosphorylation of IRS-1 in in an inhibition of insulin that observed in intact cells that have been treated with Fourth, inhibition of insulin in an to and a inhibitor of PD98059, blocked the ability of to inhibit insulin also the ability of to the activation of the IRS-1 kinase, an inhibitor of the kinase was to inhibit the activation of this kinase the of IRS-1 cells in the of an the that MAP kinase the phosphorylation of IRS-1 in in its subsequent decreased ability to its with 3-kinase. present studies the that phosphorylate IRS-1 and also to an inhibition of insulin that studies have also a potential role MAP kinase in a inhibition of insulin studies have that the MAP in the phosphorylation of in the of the and the of activation In a in insulin was in cells a the MAP kinase has also been that with insulin activation of by a that with the that could to insulin by MAP kinase activation has been observed in of the that an of MAP kinase with of an increase in the of the IRS-1 serine kinase MAP in the of to and the and the construct, the the IRS-1 construct, and the also